Skip to main content

Remote Job Finders (RJF)

Novartis Looking for Constructive Ways To Bring Down Drug Costs in US

In an interview with German-language outlet Neue Zuercher Zeitung, Novartis CEO Vas Narasimhan said the company is exploring ways to remove or minimize the drug price gap between the U.S. and its other markets in similarly developed countries.

Staying Agile: Blended Workforces Offer Strategic Approach to Business Needs

Building and scaling biopharma workforces can go beyond recruiting permanent employees to include fractional workers and consultants. A Slone Partners executive discusses how these blended workforces operate, highlighting the strategic benefits.

Psychedelics Space Enters New Era as AbbVie Dives In

With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.

VectorY Bets up to $1.2B+ That Shape’s Brain-Penetrant Capsids Are a Fit

VectorY Therapeutics will evaluate the use of SHP-DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental Huntington’s and Alzheimer’s disease treatments.
Scroll to top